Target Price | €160.53 |
Price | €115.50 |
Potential | 38.99% |
Number of Estimates | 17 |
17 Analysts have issued a price target Merck 2026 . The average Merck target price is €160.53. This is 38.99% higher than the current stock price. The highest price target is €195.00 68.83% , the lowest is €107.00 7.36% . | |
A rating was issued by 19 analysts: 16 Analysts recommend Merck to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 38.99% . Most analysts recommend the Merck stock at Purchase. |
16 Analysts have issued a sales forecast Merck 2025 . The average Merck sales estimate is €21.7b . This is 1.66% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €22.1b 3.83% , the lowest is €21.4b 0.22% .
This results in the following potential growth metrics:
2024 | €21.2b | 0.78% |
---|---|---|
2025 | €21.7b | 2.42% |
2026 | €22.6b | 4.08% |
2027 | €23.3b | 3.50% |
2028 | €24.6b | 5.26% |
2029 | €25.9b | 5.31% |
16 Analysts have issued an Merck EBITDA forecast 2025. The average Merck EBITDA estimate is €6.2b . This is 4.61% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.6b 12.27% , the lowest is €5.7b 2.41% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €4.9b | 3.42% |
---|---|---|
2025 | €6.2b | 24.79% |
2026 | €6.6b | 6.74% |
2027 | €6.9b | 5.03% |
2028 | €7.3b | 6.37% |
2029 | €7.8b | 6.84% |
2024 | 23.31% | 2.62% |
---|---|---|
2025 | 28.40% | 21.85% |
2026 | 29.12% | 2.54% |
2027 | 29.55% | 1.48% |
2028 | 29.87% | 1.08% |
2029 | 30.30% | 1.44% |
12 Merck Analysts have issued a net profit forecast 2025. The average Merck net profit estimate is €3.1b . This is 8.50% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.4b 20.85% , the lowest is €2.7b 2.46% .
This results in the following potential growth metrics and future Net Margins:
2024 | €2.8b | 1.66% |
---|---|---|
2025 | €3.1b | 10.06% |
2026 | €3.4b | 10.80% |
2027 | €3.6b | 7.03% |
2028 | €3.9b | 6.78% |
2029 | €4.1b | 6.58% |
2024 | 13.13% | 2.42% |
---|---|---|
2025 | 14.11% | 7.49% |
2026 | 15.02% | 6.45% |
2027 | 15.53% | 3.40% |
2028 | 15.75% | 1.42% |
2029 | 15.94% | 1.21% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck EPS is €7.03 . This is 8.49% higher than earnings per share in the financial year 2024. The highest EPS forecast is €7.83 20.83% , the lowest is €6.32 2.47% .
This results in the following potential growth metrics and future valuations:
2024 | €6.39 | 1.69% |
---|---|---|
2025 | €7.03 | 10.02% |
2026 | €7.79 | 10.81% |
2027 | €8.34 | 7.06% |
2028 | €8.90 | 6.71% |
2029 | €9.49 | 6.63% |
Current | 17.82 | 33.38% |
---|---|---|
2025 | 16.43 | 7.82% |
2026 | 14.83 | 9.74% |
2027 | 13.85 | 6.61% |
2028 | 12.97 | 6.35% |
2029 | 12.17 | 6.17% |
Based on analysts' sales estimates for 2025, the Merck stock is valued at an EV/Sales of 2.64 and an P/S ratio of 2.31 .
This results in the following potential growth metrics and future valuations:
Current | 2.68 | 30.39% |
---|---|---|
2025 | 2.64 | 1.54% |
2026 | 2.54 | 3.92% |
2027 | 2.45 | 3.38% |
2028 | 2.33 | 5.00% |
2029 | 2.21 | 5.04% |
Current | 2.35 | 32.70% |
---|---|---|
2025 | 2.31 | 1.63% |
2026 | 2.22 | 3.92% |
2027 | 2.15 | 3.38% |
2028 | 2.04 | 4.99% |
2029 | 1.94 | 5.05% |
Analyst | Rating | Action | Date |
---|---|---|---|
REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Apr 06 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Apr 01 2025 |
DAY BY DAY |
Sell
➜
Sell
|
Unchanged | Mar 30 2025 |
HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
EQUITA SIM |
Buy
➜
Buy
|
Unchanged | Mar 16 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Mar 10 2025 |
JEFFERIES |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
Analyst Rating | Date |
---|---|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Apr 06 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Apr 01 2025 |
Unchanged
DAY BY DAY:
Sell
➜
Sell
|
Mar 30 2025 |
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
Unchanged
EQUITA SIM:
Buy
➜
Buy
|
Mar 16 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Mar 10 2025 |
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Mar 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.